peptides.cx

Mitochondrial

Buy NAD+ – Vendors, Prices, Testing and Evidence

Also known as: NAD Β· nicotinamide adenine dinucleotide Β· NAD plus

Evidence grade C β€” Early / Preclinical

Short answer

A coenzyme β€” not a peptide β€” central to cellular energy metabolism, promoted via IV drips and precursor supplements (NR, NMN) for anti-aging and 'wellness'. Precursors reliably raise NAD+ levels, but human evidence for the anti-aging claims is limited.

Where can you buy NAD+?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, not a peptide. It shuttles electrons in redox reactions and serves as a substrate for enzymes such as sirtuins and PARPs involved in metabolism and DNA repair. Commercially it appears as direct intravenous or injectable NAD+, and as oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that the body converts into NAD+.

What is not established?

Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes β€” glucose and lipid metabolism, muscle strength, physical function β€” have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome.

Safety

Oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects. Intravenous NAD+ is used at clinics but has little formal safety characterization; faster infusions are commonly associated with transient discomfort such as flushing, nausea, chest tightness, and cramping. Long-term safety of sustained NAD+ elevation in humans is not established.

Regulatory status

NAD+ is a coenzyme, not a peptide and not an approved drug. No intravenous or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use; IV NAD+ is offered at clinics as an unapproved application. Among precursors, nicotinamide riboside (NR) is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the dietary-supplement definition.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Vendor comparison

Buy NAD+: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Sponsored / Affiliate

Crystal Peptides

NAD+ research product

Code PEPTIDES10 βˆ’10% Β· discount code details

Sponsored

Documentation

Vendor-supplied data

COA stated as available

Not independently documented

Checked

Jul 18, 2026

Affiliate disclosure: This page contains affiliate links. peptides.cx may receive a commission when a purchase is made through one of these links. Evidence ratings, safety summaries and editorial content are produced independently from vendor relationships.

What is it?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, not a peptide. It shuttles electrons in redox reactions and serves as a substrate for enzymes such as sirtuins and PARPs involved in metabolism and DNA repair. Commercially it appears as direct intravenous or injectable NAD+, and as oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that the body converts into NAD+.

Research and evidence

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell β€” not a peptide. It shuttles electrons in the redox reactions that power metabolism and serves as a required co-substrate for enzymes such as sirtuins and PARPs involved in energy production and DNA repair. Despite often being grouped with "peptide therapy" in wellness marketing, NAD+ is a fundamentally different kind of molecule. It reaches consumers in two main forms: as direct intravenous or injectable NAD+ offered at clinics, and as oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that the body converts into NAD+.

The honest evidence picture is that precursors do what they claim biochemically, but not much more. Trials show oral NR and NMN can reliably raise blood NAD+ levels and are generally safe in the short term, yet most measured clinical outcomes β€” glucose and lipid metabolism, muscle strength, physical function β€” have not improved significantly versus placebo. Direct intravenous NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome. Enthusiasm rests largely on rodent and cell studies that have not translated cleanly into human benefit, which is why the anti-aging claims driving sales outrun the data.

On safety and regulation, oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects, while intravenous NAD+ has little formal safety characterization and faster infusions are commonly linked to transient flushing, nausea, chest tightness, and cramping. The long-term effects of chronically elevated NAD+ in humans are simply not established. NAD+ is not an approved drug, and no IV or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use. Among precursors, NR is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the supplement definition. This page is educational and not medical advice; it provides no dosing, administration, or sourcing guidance.

Evidence grade: C

Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes β€” glucose and lipid metabolism, muscle strength, physical function β€” have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome. Preclinical studies in rodents and cell models are the main source of enthusiasm: raising NAD+ or its precursors has improved metabolic and some age-related measures in animals. However, human NAD+ dynamics differ from rodents, and these animal results have not translated cleanly into demonstrated clinical benefit in people.

Human evidence

Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes β€” glucose and lipid metabolism, muscle strength, physical function β€” have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome.

Animal and preclinical evidence

Preclinical studies in rodents and cell models are the main source of enthusiasm: raising NAD+ or its precursors has improved metabolic and some age-related measures in animals. However, human NAD+ dynamics differ from rodents, and these animal results have not translated cleanly into demonstrated clinical benefit in people.

Proposed mechanisms

  • Serves as an essential electron carrier (NAD+/NADH) in glycolysis, the citric acid cycle, and oxidative phosphorylation
  • Acts as a required co-substrate for sirtuins, PARPs, and CD38, linking it to DNA repair and metabolic signaling
  • Oral precursors (NR, NMN) are metabolized through salvage pathways to raise intracellular NAD+
  • Rationale for supplementation rests on reports that tissue NAD+ may decline with age, though this has been inconsistent in human data

Safety concerns and known side effects

Oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects. Intravenous NAD+ is used at clinics but has little formal safety characterization; faster infusions are commonly associated with transient discomfort such as flushing, nausea, chest tightness, and cramping. Long-term safety of sustained NAD+ elevation in humans is not established.

  • Infusion-related flushing, nausea, chest tightness, and cramping with faster IV administration
  • Mild gastrointestinal upset, fatigue, or headache reported with oral precursors
  • Flushing with high-dose niacin forms
  • Unknown long-term effects of chronically elevated NAD+ in humans

Regulatory status

NAD+ is a coenzyme, not a peptide and not an approved drug. No intravenous or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use; IV NAD+ is offered at clinics as an unapproved application. Among precursors, nicotinamide riboside (NR) is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the dietary-supplement definition.

Frequently asked questions about NAD+

Is NAD+ a peptide?
No. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is a small molecule found in every cell that carries electrons in metabolic reactions and supports enzymes involved in energy production and DNA repair. It is often marketed alongside peptides but is a different class of molecule.
Does NAD+ actually work for anti-aging?
The human evidence for anti-aging is limited. Oral precursors like NR and NMN reliably raise blood NAD+ levels, but most measured clinical outcomes have not improved significantly versus placebo in trials. Much of the enthusiasm comes from animal studies that have not translated cleanly into demonstrated human benefits.
Is IV NAD+ better than oral NR or NMN?
There is little evidence to answer this well. Oral NR and NMN are shown to raise NAD+ levels, whereas direct IV NAD+ is barely studied β€” small pilot work has tracked its metabolism, but no adequately powered trials support IV NAD+ for any wellness outcome. The IV route's added cost is not matched by stronger evidence.
What is the difference between NAD+, NR, and NMN?
NAD+ is the active coenzyme itself. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are precursors that the body converts into NAD+. Precursors are the most-studied oral route for raising NAD+, though raising blood levels has not consistently produced clinical benefits.
Are NAD+ supplements legal or approved?
NAD+ is not an approved drug, and no IV or injectable NAD+ product is approved by the FDA or EMA for anti-aging or wellness use. Among precursors, NR is sold as a dietary supplement, while the US FDA has taken the position that NMN is excluded from the dietary-supplement definition.
What are the side effects of NAD+?
Oral NR and NMN are generally well tolerated in short-term trials, with mild effects such as gastrointestinal upset, fatigue, or headache. Faster IV NAD+ infusions are commonly linked to flushing, nausea, chest tightness, and cramping. Long-term effects of elevated NAD+ in humans are not established. This is educational information, not medical advice.
Where can I buy NAD+ and compare vendors?
Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

IV NAD+ drips versus oral NR or NMN, and whether the IV route is worth the costNMN's uncertain US regulatory status after FDA actionsWhether raising blood NAD+ actually translates into anti-aging or energy benefitsReports of NAD+ decline with age and how much it matters

Sources

Editorial review and transparency

Written by
peptides.cx Editorial Team
Scientific reviewer
No named medical reviewer is currently assigned
Last editorial review
July 18, 2026
Last vendor check
July 18, 2026
Review method
Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts
Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Related on peptides.cx